A Phase 2/3 interventional study of ABX464 and Placebo in COVID-19, sponsored by Abivax S.A.. Terminated at 30 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Abivax S.A. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.
Among the 392 studies in COVID-19 with a site in Italy, this one is the 23rd largest by enrollment of the 153 interventional ones that give a count, is one of 231 that started in 2020, is one of 20 in phase 2/3, and was the 82nd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Italy, United States, Brazil and 4 more countries
Ages 18–65
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18–99 · Women only
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 21 more countries
Ages 18+
IRCCS Sacro Cuore Don Calabria di Negrar · Sites in Italy
Ages 18+ · Healthy volunteers
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
392 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 53 · Phase 3 53 · Phase 4 3
First in 2009; this study’s year is marked. 231 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 509 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 100 across the 153 interventional studies, 251 across the 238 observational. Of the 235 that completed or were terminated, 29 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 392 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
7 of the studies in COVID-19 with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05188612University of BolognaInternational Survey of Acute Coronavirus Syndromes-COVID-19 | 2026-12-31 |
| NCT06070961Fondazione Italiana Linfomi - ETSProspective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 392 studies in COVID-19 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2 (the MiR-AGE study).
This phase 2/3 study will evaluate the efficacy and safety of ABX464 50mg QD (oral capsule), on treating inflammation and preventing acute respiratory failure in patients infected with SARS-CoV-2.
Eligible patients will be randomized according to a 2:1 ratio into 2 treatment cohorts as follows:
Study design:
The study will consist of 2 periods:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult (≥ 18 years old) men or women, hospitalized or not hospitalized, diagnosed for SARS-CoV-2 infection by PCR, with at least one associated risk factor. Considered risk factors are:
Patients with the following hematological and biochemical laboratory parameters obtained within 7 days prior to Day 0:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABX464 - Capsules + Standard of Care (SOC)
Drug: ABX464
Placebo - Capsules + Standard of Care (SOC)
Drug: Placebo
ABX464 50mg QD for 28 days + Standard of Care
Placebo 50mg QD for 28 days + Standard of Care
Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period.
Subjects will be assessed as responders if they did not receive oxygen supplementation through IMV and NIV during the treatment period, and they are alive at the end of the 28-days treatment period. Non responders are subjects who receive oxygen supplementation (through IMV and NIV during the treatment period) and/or who die during the 28-days treatment period. The use of high-flow oxygen being defined as settings of 3 L/min or greater AND with at least one SpO2 measurement \< 92%, with or without O2 supplementation). Descriptive statistics will be presented by treatment arm.
Time frame: 28 days
Rate of Patients Hospitalized
To evaluate the proportion of patients requiring hospitalization during the study compared to the {Standard of Care + placebo} group An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Efficacy results are only available for the 305 patients randomized at the time of the interim analysis.
Time frame: 28 days
Percentage of Patients Reporting Each Severity Rating on a 7-point Ordinal Scale
7-point ordinal scale is defined as Not hospitalized, no limitations on activities; Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: 28-day treatment period
Change From Enrolment in Inflammatory Markers in Plasma and in Immune Phenotype and Assessment of Cell-activation Markers in PBMCs
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: at each study visit during the 28-day treatment period
Rate of Patients Requiring Oxygen Supplementation
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: 28-day treatment period
Time to Hospitalization
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: 28-day treatment period
Time to Assisted Ventilation and Oxygen Supplementation
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: 28-day treatment period
Change From Baseline in microRNA-124 Levels
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: at each study visit during the 28-day treatment period
Change From Baseline in CRP, Troponin I & T and D-dimer
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: at each study visit during the 28-day treatment period
SARS-CoV-2 Viral Load
Nasopharyngeal sample and/or in blood An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
Time frame: at each study visit during the 28-day treatment period
Number and Rates of Participants With Treatment Emergent Adverse Event
Number and rates of participants included in the safety analysis set who had Treatment Emergent Adverse Event
Time frame: From D0 to D48 (28 days treatment period + up to 20 days Safety follow-up period)
| Milestone | ABX464 | Placebo |
|---|---|---|
| Started | 339 | 170 |
| Completed | 188 | 99 |
| Not completed | 151 | 71 |
| Withdrew: Adverse event | 11 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Death | 6 | 4 |
| Withdrew: Withdrawal by subject | 24 | 8 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Other reasons+ trial site terminated by sponsor + study terminated by sponsor | 94 | 49 |
| Withdrew: End of study date not collected in the ecrf | 10 | 4 |
Subjects will be assessed as responders if they did not receive oxygen supplementation through IMV and NIV during the treatment period, and they are alive at the end of the 28-days treatment period. Non responders are subjects who receive oxygen supplementation (through IMV and NIV during the treatment period) and/or who die during the 28-days treatment period. The use of high-flow oxygen being defined as settings of 3 L/min or greater AND with at least one SpO2 measurement \< 92%, with or without O2 supplementation). Descriptive statistics will be presented by treatment arm.
| Participants | ABX464 | Placebo |
|---|---|---|
| Responder | 169 | 87 |
| Non-responder | 24 | 7 |
| Missing | 10 | 8 |
To evaluate the proportion of patients requiring hospitalization during the study compared to the {Standard of Care + placebo} group An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Efficacy results are only available for the 305 patients randomized at the time of the interim analysis.
| Participants | ABX464 | Placebo |
|---|---|---|
| Rate of Patients Hospitalized | 23 | 11 |
7-point ordinal scale is defined as Not hospitalized, no limitations on activities; Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
Nasopharyngeal sample and/or in blood An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Only key outcome analysis was performed during this interim analysis. After discontinuation of the study for futility, Abivax decided to not perform the analysis on this secondary outcome (SAP was amended accordingly). Therefore, these data are not available.
No measurements were reported for this outcome.
Number and rates of participants included in the safety analysis set who had Treatment Emergent Adverse Event
| Participants | ABX464 | Placebo |
|---|---|---|
| Period 1: AE onset or worsens before or on Day 28 | 209 | 83 |
| Period 2: AE onset or worsens after Day 28 | 22 | 20 |
Collected over 49 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464 | 6/335 (1.8%) | 36/335 (10.7%) | 115/335 (34.3%) |
| Placebo | 4/170 (2.4%) | 20/170 (11.8%) | 27/170 (15.9%) |
| Event | ABX464 | Placebo |
|---|---|---|
| covid-19Infections and infestations | 10/335 | 2/170 |
| Covid-19 pneumoniaInfections and infestations | 5/335 | 5/170 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 1/335 | 3/170 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 3/335 | 2/170 |
| Oxygen saturation decreasedInvestigations | 1/335 | 2/170 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/335 | 0/170 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/335 | 0/170 |
| Pancreatitis acuteGastrointestinal disorders | 2/335 | 0/170 |
| Abdominal pain upperGastrointestinal disorders | 2/335 | 0/170 |
| Diabetic metabolic decompensationMetabolism and nutrition disorders | 2/335 | 0/170 |
| Event | ABX464 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 49/335 | 19/170 |
| Abdominal pain upperGastrointestinal disorders | 32/335 | 5/170 |
| DiiarrhoeaGastrointestinal disorders | 30/335 | 6/170 |
| Back painMusculoskeletal and connective tissue disorders | 23/335 | 4/170 |
| NauseaGastrointestinal disorders | 20/335 | 6/170 |
| Age, Categorical(Participants) | ABX464 | Placebo | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 240 | 120 | 360 |
| >=65 years | 98 | 50 | 148 |
| Age, Continuous(years) | ABX464 | Placebo | Total |
|---|---|---|---|
| Mean | 54.9 ± 15.36 | 54.4 ± 15.05 | 54.7 ± 15.24 |
| Sex: Female, Male(Participants) | ABX464 | Placebo | Total |
|---|---|---|---|
| Female | 160 | 84 | 244 |
| Male | 179 | 86 | 265 |
| Ethnicity (NIH/OMB)(Participants) | ABX464 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 274 | 130 | 404 |
| Not Hispanic or Latino | 54 | 35 | 89 |
| Unknown or Not Reported | 11 | 5 | 16 |
| Region of Enrollment(participants) | ABX464 | Placebo | Total |
|---|---|---|---|
| Belgium | 2 | 2 | 4 |
| Brazil | 238 | 114 | 352 |
| Italy | 20 | 11 | 31 |
| Mexico | 8 | 7 | 15 |
| United Kingdom | 1 | 0 | 1 |
| Germany | 2 | 2 | 4 |
| Spain | 24 | 15 | 39 |
| France | 20 | 12 | 32 |
| Peru | 24 | 7 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Mar 2021, 8 months.
Results were first posted in Nov 2025, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464